Trial · NCT01495910
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
NCT01495910, Phase 1, Completed, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency. Trials, record NCT01495910. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01495910
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
- NCT number
- NCT01495910
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 6 participants, actual
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Conditions
- 21-hydroxylase Deficiency
- Interventions
- Abiraterone acetate
- First posted
- 2011-12-20
- Last updated
- 2014-02-28
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The minimum dose of abiraterone acetate required to decrease serum androstenedione to the age-appropriate range for adult women with 21-hydroxylase deficiency | Up to Day 7 of each treatment period. | Normalization or reduction of age-appropriate androstenedione levels will be determined by the mean of the androstenedione values measured on Study Days 6 and 7 of the treatment period. |
| Secondary | Mean serum concentrations of androstenedione | Up to Day 8 of each treatment period. | |
| Secondary | Mean serum concentrations of 17-hydroxyprogesterone | Up to Day 8 of each treatment period. | |
| Secondary | Mean plasma concentrations of renin activity | Up to Day 8 of each treatment period. | |
| Secondary | Mean serum concentrations of testosterone | Up to Day 8 of each treatment period. | |
| Secondary | Urine concentrations of androsterone | Up to Day 8 of each treatment period. | |
| Secondary | Urine concentrations of etiocholanolone | Up to Day 8 of each treatment period. | |
| Secondary | Maximum plasma concentration (Cmax) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Time to reach the maximum plasma concentration (tmax) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC24) of abiraterone | Up to Day 8 of each treatment period. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01495910
GET https://conductscience.org/api/trials/v1/NCT01495910/registered